Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2026 16:05 ET | Source: Femasys Inc.

Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update

ATLANTA, May 08, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to...
May 08, 2026 08:00 ET | Source: BioCardia, Inc.

BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways

SUNNYVALE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
May 05, 2026 09:00 ET | Source: Femasys Inc.

Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete

-- Integrated sperm preparation and intratubal insemination drive earlier intervention and streamlined, in-office care within routine OB/GYN practice -- ATLANTA, May 05, 2026 (GLOBE NEWSWIRE) --...
April 22, 2026 09:00 ET | Source: Femasys Inc.

Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026

ATLANTA, April 22, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and...
April 08, 2026 07:30 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas

HOUSTON, April 08, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
April 02, 2026 10:11 ET | Source: BioCardia, Inc.

BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure

SUNNYVALE, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
April 01, 2026 09:00 ET | Source: Femasys Inc.

Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth

ATLANTA, April 01, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and...
March 18, 2026 09:00 ET | Source: Femasys Inc.

Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and...
March 10, 2026 09:00 ET | Source: Femasys Inc.

Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment

-- Enrollment begins in the FDA-authorized FINALE pivotal trial evaluating FemBloc, a first-of-its-kind non-surgical permanent birth control, following positive clinical data -- ATLANTA, March 10,...
March 09, 2026 07:30 ET | Source: Trevi Therapeutics, Inc.

Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough

The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough First pivotal trial is on track to initiate in the second quarter of...